Abstract:Background: Acute myeloid leukemia (AML) is a highly heterogeneous hematological cancer. The current diagnosis and therapy model of AML has gradually shifted to personalization and accuracy. Artesunate, a member of the artemisinin family, has anti-tumor impacts on AML. This research uses network pharmacology and molecular docking to anticipate artesunate potential mechanisms of action in the therapy of AML. Methods: Screening the action targets of artesunate through Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform (TCMSP), PubChem, and Swiss Target Prediction databases; The databases of Online Mendelian Inheritance in Man (OMIM), Disgenet, GeneCards, and Drugbank were utilized to identify target genes of AML, and an effective target of artesunate for AML treatment was obtained through cross-analysis. Protein-protein interaction (PPI) networks are built on the Cytoscape platform. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses were conducted on the relevant targets using R software. Finally, using molecular docking technology and Pymol, we performed verification of the effects of active components and essential targets. Results: Artesunate 30 effective targets for treating AML include CASP3, EGFR, MAPK1, and STAT3, four targeted genes that may have a crucial function in disease management. The virus infection-related pathway (HeptatisB (HBV), Human papillomavirus (HPV), Epstein-Barr virus (EBV) infection and etc.), FoxO, viral carcinogenesis, and proteoglycans in cancer signaling pathways have all been hypothesized to be involved in the action mechanism of GO, which is enriched in 2044 biological processes, 125 molecular functions, 209 cellular components, and 106 KEGG pathways. Molecular docking findings revealed that artesunate was critically important in the therapy of AML due to its high affinity for the four primary disease targets. Molecular docking with a low binding energy yields helpful information for developing medicines against AML. Conclusions: Consequently, artesunate may play a role in multi-targeted, multi-signaling pathways in treating AML, suggesting that artesunate may have therapeutic potential for AML.

Cytotoxic Effect of Artesunate on Myeloid Leukemia Cell Lines Through Up-Regulating Mir-29C Expression

Mir-22 Has a Potent Anti-Tumour Role with Therapeutic Potential in Acute Myeloid Leukaemia

Identification of TET1⊣miR-22⊣CREB-MYC Signaling Reveals Potent Tumor-Suppressor Role of Mir-22 in Acute Myeloid Leukemia

Artesunate, a new antimalarial clinical drug, exhibits potent anti‐AML activity by targeting the ROS/Bim and TFRC/Fe<sup>2+</sup> pathways

Artesunate, a new antimalarial clinical drug, exhibits potent anti-AML activity by targeting the ROS/Bim and TFRC/Fe2+ pathways

Exploring underlying mechanism of artesunate in treatment of acute myeloid leukemia using network pharmacology and molecular docking

High Expression of Mir-25 Predicts Favorable Chemotherapy Outcome in Patients with Acute Myeloid Leukemia.

Artesunate possesses anti-leukemia properties that can be enhanced by arsenic trioxide.

Pretreatment of Umbilical Cord Derived MSCs with IFN-γ and TNF-α Enhances the Tumor-Suppressive Effect on Acute Myeloid Leukemia.

Artesunate, a new antimalarial clinical drug, exhibits potent anti-AML activity by targeting the ROS/Bim and TFRC/Fe 2+ pathways.

Artesunate inhibits angiogenesis and downregulates vascular endothelial growth factor expression in chronic myeloid leukemia K562 cells

Altered Expression Pattern of Mir-29A, Mir-29B and the Target Genes in Myeloid Leukemia

Mir-29A and Mir-142-3p Downregulation and Diagnostic Implication in Human Acute Myeloid Leukemia

Mir-181A Sensitizes Resistant Leukaemia HL-60/Ara-C Cells to Ara-C by Inducing Apoptosis

Downregulation of Mir-142 Promotes Leukemia Growth in Philadelphia Chromosome-Positive (ph+) Acute Lymphoblastic Leukemia (ALL): A Possible Novel Therapeutic Target?

Inhibitive Effect of Artesunate on Human Lymphoblastic Leukemia/Lymphoma Cells

Enhanced Chemosensitivty of Leukemic Cells to Cytarabine by Targeted Suppression of Mirna-21

[Effects of Artesunate Combined with Bortezomib on Apoptosis and Autophagy of Acute Myeloid Leukemia Cells in Vitro and Its Mechanism].

The Effects Of Artesunate On The Expression Of Egfr And Abcg2 In A549 Human Lung Cancer Cells And A Xenograft Model

Targeting Metabolic Dependencies in Acute Myeloid Leukemia: A Dual Strategy using Arsenic Trioxide and Artesunate.

Artesunate Enhances Adriamycin Cytotoxicity by Inhibiting Glycolysis in Adriamycin-Resistant Chronic Myeloid Leukemia K562/ADR Cells.